Autolus Therapeutics reported $26.2 million in Q1 revenue for its blood cancer drug AUCATZYL, up from $9.0 million a year earlier.
Autolus Therapeutics (NASDAQ:AUTL) reported $26.2 million in net product revenue for AUCATZYL in the first quarter, a year-over-year increase from $9.0 million. The company achieved positive gross margin for the first time, signaling improving financials for its approved blood cancer treatment.
The company maintained its 2026 revenue guidance for AUCATZYL at $120 million to $135 million, compared with $74 million projected for 2025. Autolus is expanding the drug’s use into pediatric acute lymphoblastic leukemia, lupus nephritis, and multiple sclerosis, with recent data showing a 59% remission rate in a difficult-to-treat patient subgroup.
Autolus ended Q1 with $229.4 million in cash and equivalents, extending its runway into late 2027. The company’s commercial-stage status and revenue growth contrast with many pre-revenue biotech peers.